Validation of L-Type Calcium Channel Blocker Amlodipine as a Novel ADHD Treatment through Cross-Species Analysis, Drug-Target Mendelian Randomization, and clinical evidence from medical records

Haraldur Þorsteinsson, Hannes A. Baukmann, Hildur S. Sveinsdóttir, Dagmar Þ. Halldórsdóttir, Bartosz Grzymala, Courtney Hillman, Jude Rolfe-Tarrant, Matthew O. Parker, Justin L. Cope, Charles N. J. Ravarani, Marco F. Schmidt, Karl Æ. Karlsson
doi: https://doi.org/10.1101/2024.05.30.24308216

Article usage

Article usage: May 2024 to March 2025

AbstractFullPdf
May 20248304
Jun 20243233888
Jul 20242601799
Aug 2024754029
Sep 2024775234
Oct 2024444135
Nov 2024668127
Dec 2024578236
Jan 2025677026
Feb 202515426612
Mar 20255013316
Back to top
Posted May 31, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Validation of L-Type Calcium Channel Blocker Amlodipine as a Novel ADHD Treatment through Cross-Species Analysis, Drug-Target Mendelian Randomization, and clinical evidence from medical records
Haraldur Þorsteinsson, Hannes A. Baukmann, Hildur S. Sveinsdóttir, Dagmar Þ. Halldórsdóttir, Bartosz Grzymala, Courtney Hillman, Jude Rolfe-Tarrant, Matthew O. Parker, Justin L. Cope, Charles N. J. Ravarani, Marco F. Schmidt, Karl Æ. Karlsson
medRxiv 2024.05.30.24308216; doi: https://doi.org/10.1101/2024.05.30.24308216
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area